Brazil Liver Diseases Therapeutics Market Report 2022 to 2030

Brazil Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Brazil Liver Disease Therapeutics market will reach a value of $970 Mn from $577 Mn in 2022, growing at a CAGR of 6.7% during 2022-2030. Liver Disease Therapeutics in Brazil is dominated by domestic pharmaceutical companies such as Eurofarma, Aché Laboratórios, and EMS. The Liver Disease Therapeutics market in Brazil is segmented into different types of disease and different therapy types. Some of the significant factors affecting the Brazil Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10BRPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Dr. Vishwa Modhia

Buy Now

Brazil Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Brazil Liver Disease Therapeutics market will reach a value of $970 Mn from $577 Mn in 2022, growing at a CAGR of 6.7% during 2022-2030.

Brazil is an upper middle-income, developing and the largest country in South America bounded by the Atlantic Ocean. In the 1990s, the hepatitis B vaccine was added to the Brazilian National Immunization Calendar and was recommended for all children in their first year of life. Vaccine coverage was expanded in 2016 and is now available to all persons, regardless of age. In Brazil, liver illnesses were the seventh largest cause of death. During the study period, the prevalence of hospitalisation for liver illness was 0.72 %, and the mortality rate was 3.34 %.

According to the latest WHO data published in 2020 Liver Disease Deaths in Brazil reached 21,422 or 1.90% of total deaths. The age-adjusted Death Rate is 9.02 per 100,000 population ranks Brazil 133^rd in the world. Brazil's government spent 10.3 % of its GDP on healthcare in 2020.

Brazil Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

The Brazilian Society of Infectious Diseases (SBI) and the Brazilian Society of Hepatology collaborated to develop a guideline for hepatitis B diagnosis and therapy. The National Viral Hepatitis Plan (NVHP) was developed by the government to prevent, diagnose, and cure viral hepatitis. The scheme offers free hepatitis B and C testing and treatment at selected government hospitals and clinics. These aspects could boost Brazil's Liver Disease Therapeutics market.

Market Restraints

Although the majority of Brazil is regarded to have a low incidence of HBV infection, there are some areas with a greater frequency of carriers. Unfortunately, many infected patients have not yet been recognised or treated. The healthcare system in Brazil is fragmented, with public and private providers coexisting. This can make accessing and delivering liver cancer medicines problematic for patients and clinicians. Brazil's competitiveness is hampered by high manufacturing costs (wages, energy, logistics, and loans). These factors may deter new entrants into the Brazil Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Eurofarma: Eurofarma is a Brazilian pharmaceutical company that produces a range of therapeutic products, including those for liver disease. Its liver disease products include Ursodiol and Silymarin
Aché Laboratórios Farmacêuticos: Aché Laboratórios Farmacêuticos is a Brazilian pharmaceutical company that develops and produces a wide range of therapeutic products, including those for liver disease. Its liver disease products include Ursodiol and Silymarin
EMS: EMS is a Brazilian pharmaceutical company that produces a variety of therapeutic products, including those for liver disease. Its liver disease products include Ursodiol and Silymarin
Cristália Produtos Químicos Farmacêuticos: Cristália Produtos Químicos Farmacêuticos is a Brazilian pharmaceutical company that develops and produces a range of therapeutic products, including those for liver disease
Biolab Sanus Farmacêutica: Biolab Sanus Farmacêutica is a Brazilian pharmaceutical company that produces a range of therapeutics, including those for liver disease

Recent Notable Updates

November 2022: Eurofarma, a multinational pharmaceutical business established in Brazil and one of the largest in Latin America, announced its debut into the United States market with the acquisition of Medimetriks Pharmaceuticals, Inc. Eurofarma's strategic purchase in the United States advances the company's ambition of becoming a worldwide pharmaceutical corporation. This is Eurofarma's first acquisition outside of Latin America, and it comes only weeks after the company was inspected by the United States Food and Drug Administration (FDA), the organisation in charge of drug regulation in the country.

Healthcare Policies and Reimbursement Scenarios

In Brazil, the regulation and reimbursement of liver therapeutics are overseen by the National Health Surveillance Agency (ANVISA) and the Brazilian Ministry of Health. ANVISA is responsible for the registration and approval of drugs in Brazil, including those used for liver diseases such as hepatitis B and C, liver cirrhosis, and other liver-related conditions. In terms of reimbursement, Brazil has a public healthcare system called the Unified Health System (SUS) that provides free healthcare services to all Brazilian citizens.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.